K. Raja Reddy,Jeff Stebbins,Serge H. Boyer,Mark D. Erion,Scott J. Hecker,Nicholas Brian Raffaele,Brett C. Bookser,Venkat Reddy Mali
申请号：
US16025199
公开号：
US20180303856A1
申请日:
2018.07.02
申请国别(地区):
US
年份:
2018
代理人:
摘要：
This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.
